Products for Research Use Only

Nisoldipine-d4

CAT: 0804-HY-17402S1-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17402S1-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Nisoldipine-d4 (BAY-k 5552-d4) is the deuterium labeled Nisoldipine. Nisoldipine (BAY-k 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM[1][2].
CAS Number
1219795-47-7
UNSPSC
12352005
Target
Calcium Channel; Isotope-Labeled Compounds; Reactive Oxygen Species (ROS)
Type
Isotope-Labeled Compounds
Related Pathways
Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB; Others
Applications
Neuroscience-Neurodegeneration
Field of Research
Cardiovascular Disease
Solubility
10 mM in DMSO
Smiles
C(OCC(C)C)(=O)C=1C(C(C(OC)=O)=C(C)NC1C)C2=C(N(=O)=O)C(=C(C(=C2[2H])[2H])[2H])[2H]
Molecular Formula
C20H20D4N2O6
Molecular Weight
392.44
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Hamilton SF, Houle LM, Thadani U. Rapid-release and coat-core formulations of nisoldipine in treatment of hypertension, angina, and heart failure. Heart Dis. 1999 Nov-Dec;1 (5) :279-88.|[3]Fodor JG. Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. Cardiovasc Drugs Ther. 1997 Jan;10 Suppl 3:873-9.|[4]D.J. Duncker, J.M. Hartog, P.G. Hugenholtz, et al. The effects of nisoldipine (Bay K 5552) on cardiovascular performance and regional blood flow in pentobarbital - anaesthetized pigs with or without β-adrenoceptor blockade. British Journal of Pharmacology. 1986,88 (1) : 9-18|[5]Jan W. De Jong, Tom Huizer, Jan G.P. Tijssen. Energy conservation by nisoldipine in ischaemic heart. British Journal of Pharmacology. 1984, 83 (4) : 943-949
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported